Dear Editor,
Dieden et al. [1], reported that circulating interleukin-1 receptor type 2 and chitinase-3-like protein 1 are linked to blood pressure and hypertension in a population-derived cohort. Linking a range of cardiovascular proteins to several hypertension types in one cohort is a good step. However, some details about how measurements were taken and how they are understood deserve comment.
Blood pressure was measured twice during one visit, while the participant lay down after resting for 10 min. Blood pressure readings taken while lying down are usually lower than those taken while sitting, and the 140/90 mmHg cutoff is based on seated measurements [2]. One visit is not sufficient to diagnose hypertension in people who have not started treatment [3].
Approximately 521 of 1188 people who were labeled as hypertensive had not started treatment; therefore, many in the case group relied on one lying-down measurement. Using a single visit can dilute the real link between proteins and blood pressure and it makes borderline results harder to understand.
NT-proBNP was measured in the lab. It is missing from any analysis. NT-proBNP is one of the proteins that has shown a link to systolic blood pressure and hypertension in earlier studies [4].
It could act as a control in this work. If NT-proBNP behaved as expected readers would feel more confident about the null results for other proteins. NT-proBNP also matters because heart strain increases both peptides and inflammatory markers so it could confound the results.
The authors point out that interleukin-1 receptor type 2 and aminopeptidase N're strongly related (rho 0.71) and it is hard to know which one is responsible for the link to systolic blood pressure. We can test this directly by putting both proteins into the statistical model. Aminopeptidase N was not linked to diastolic blood pressure, hypertension, or treatment resistance.
Interleukin-1 receptor type 2 was. This suggests that the two signals are not the same.
The mechanistic story goes in two directions. Interleukin-1 receptor type 2 is a decoy receptor that lessens interleukin-1β signalling. The discussion says that the link between interleukin-1 receptor type 2 and blood pressure is a sign of severity not a cause, which matches the Mendelian randomization evidence.
The same part then argues that the rise of interleukin-1 receptor type 2 with aminopeptidase N supports the idea that an interleukin-1 pathway is active in blood pressure control. More decoy receptors would normally mean signalling. Because interleukin-1β or its activity was not measured, we cannot tell which way the pathway is moving from these data.
The conclusions call the participants adults who do not have established cardiovascular disease. Only heart attacks and strokes were excluded. Heart failure, atrial fibrillation, and chronic kidney disease were still in the sample.
All of these conditions raise markers and change blood pressure.
Women comprised 30.5% of the cohort. This study did not provide sex-specific estimates or interaction tests, even though inflammatory profiles and hypertension types differ by sex. An area under the curve of 0.533 for the protein tells us almost nothing about whether it adds value beyond age, body mass index, and kidney function.
Checking discrimination would tell us if calling these proteins new biomarkers is fair.
CRediT authorship contribution statement
Shantanu Shivaji Gondkar: Writing – review & editing, Writing – original draft, Visualization. Suresh Kanna Subramaniam: Writing – original draft, Writing – review & editing, Visualization. Arvindraj Ravichandran: Conceptualization, Data curation, Formal analysis.
Informed consent
Not applicable.
Ethical approval
Not applicable (Commentary on a previously published article).
Declaration of Generative AI and AI-assisted technologies in the writing process
The authors used Claude (Anthropic) to draft and edit the text. The authors reviewed and edited the content and take full responsibility for it.
Funding
The authors have nothing to report.
Declaration of competing interest
The authors declare no conflicts of interest.